Pep Grading
United StatesCagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.
CagriSema reduced systolic BP by 10.9 mmHg versus 2.8 mmHg with placebo at week 68.
Cagrilintide
Cagrilintide is a long-acting synthetic analog of human amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells. It is being developed by Novo Nordisk both as a standalone agent and in fixed-dose combination with semaglutide (CagriSema). The CagriSema combination targets complementary appetite pathways — amylin acts on hindbrain satiety circuits while GLP-1 acts on hypothalamic and gut pathways. In the REDEFINE Phase 3 program, CagriSema achieved 20.4% weight loss at 68 weeks. Novo Nordisk filed for FDA approval in 2026.
Metabolic / Amylin AnalogWeight ManagementMetabolic Health
- Vendors
- 10 vendors
- Sizes
- 5 mg – 10 mg
- Intake
- Injections
Typical dose
2.4 mg weekly Once weekly
Once weekly, escalating every 4 weeks
Route
Subcutaneous
Administered via subcutaneous injection once weekly on a consistent day. Injection can be given at any time of day, with or without meals. Rotate injection sites between abdomen, thigh, and upper arm.
Cycle
Continuous Typical duration
Typical duration
Storage
-20°C Refrigerated
Follow vendor guidance
Marketplace
Vendor listings
10 offers for Cagrilintide
| Vendor | Price | Rating | Shipping | COA | Action |
|---|---|---|---|---|---|
prpeps
| $40.00 $8.00/mg | No reviews | 2 days United States | None | |
Biologix Labs
| $49.97 $59.99 $9.99/mg −16.7% | No reviews | 2 Days United States, Canada | None | |
idunpeptides
| $49.99 $5.00/mg | No reviews | 3–7 days United States, United Kingdom +1 | None | |
Trulab Peptides
| $62.00 $12.40/mg | No reviews | 2–5 days Worldwide | None | |
Giga Compounds
| $62.10 $69.00 $6.21/mg −10% | No reviews | 2 days United States | None | |
Amino Club
| $69.99 $7.00/mg | No reviews | 1–4 days United States | None | |
Crownwell Research
| $80.00 $8.00/mg | No reviews | 1-5 days United States | None | |
LA Peptides
| $99.99 $10.00/mg | No reviews | 2–5 days United States | None |
What the research reports
Reported research benefits.
Outcomes described across the published literature and ongoing study, not promised results. Read each as research context, not a personal guarantee.
01
Appetite regulation
02
Weight management research
03
Glycemic control
Dosage and protocol
How it is typically studied.
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk, designed for once-weekly subcutaneous injection. Clinical trials have studied doses from 0.3mg to 4.5mg weekly. It is being developed as a standalone obesity treatment and in combination with semaglutide (CagriSema). Half-life supports weekly dosing.
01 Route
Subcutaneous
02 Example range
0.3mg to 2.4mg
03 Frequency
Once weekly, escalating every 4 weeks
04 Timing
Administered via subcutaneous injection once weekly on a consistent day. Injection can be given at any time of day, with or without meals. Rotate injection sites between abdomen, thigh, and upper arm.
Educational reference only. Use clinician guidance for dosing decisions.
Evidence
What the studies actually show.
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Cagrilintide-semaglutide achieved 20.4% weight loss vs 3.0% placebo in adults with overweight/obesity.
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
Cagrilintide-semaglutide reduced body weight by 13.7% vs 3.4% placebo in type 2 diabetes.
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Cagrilintide reduced weight 6.0-10.8% vs 3.0% placebo; superior to liraglutide at highest dose.
Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.
Cagrilintide 4.5 mg did not produce clinically relevant QTc prolongation or increased arrhythmia risk.
Interactions
How it pairs with other peptides.
Cagrilintide + TB-500
Often discussed together in recovery-focused research stacks.
Cagrilintide + GHK-Cu
Sometimes paired in tissue and skin research conversations.
FAQ
Frequently asked questions.
Cagrilintide is a long-acting amylin analog researched for weight management. It works differently from GLP-1 agonists and is often studied in combination with other peptides.